

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

Granada, 10 June 2013

RELEVANT FACT NEURON BIO

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB, hereby we notify that Neuron Biopharma, S.A. has registered at the Spanish Patents and Trademarks Office (OEPM) the request for two new compounds with neuroprotective, anti-inflammatory and antiepileptic activity, which are potential effective as treatments for neurodegenerative diseases and more concretely for the Alzheimer's disease.

This patent request protects the use of both compounds named internally by the codes NST0076 and NST0078, which have been selected for their neuroprotective capacity and the modulation of the β -secretase enzyme (BACE) involved in amyloide- β deposition forming senile plaques in the brain of Alzheimer's disease patients.

After this patent application these two new compounds become part of the company pipeline with the final aim to license them to pharmaceutical companies, who then support their validation in humans and the final marketing of the product.

In Granada, 10 June 2013.

Fernando Valdivieso Amate
Chairman of the Board of Directors